Get started
Samuel12_1980

$KALA - Good entry only after stabilizing above 4.68

KALA BIO, Inc. (NASDAQ:KALA)  
Samuel12_1980  
NASDAQ:KALA   KALA BIO, Inc.
Trend Analysis Beyond Technical Analysis
5
0
trendanalysis beyondta
Clinical trial for EYSUVIS (KPI-121) - top line results of Phase III expected on first Q of 2020.
The concern is :
cash position as of September 30 was $97.6 million, compared to $170.9 million as of December 31, 2018.

I do not suggest to buy\sell .
Good-luck
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.